Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
Key Highlights
- ➤Launch-HTN: 46% achieved AHA/ACC systolic blood pressure target below 130 mmHg
- ➤Launch-HTN: 70% achieved systolic blood pressure reductions of at least 10 mmHg
- ➤Explore-OSA: Morning systolic blood pressure fell 11.1 mmHg at Week 4
- ➤Explore-OSA: Lorundrostat produced no measurable change in apnea-hypopnea indices
- ➤Explore-OSA: No significant safety events, including hyperkalemia, were observed
Expert Statements
Manish Saxena, MBBS, principal investigator; Deputy Clinical Co-Director, William Harvey Heart Centre, Queen Mary University of London; Hypertension Specialist, Barts Health NHS Trust
“Hypertension remains the most important risk factor for cardiovascular diseases, as blood pressure control rates remain poor. Participants in Launch-HTN had uncontrolled or treatment-resistant hypertension, despite being treated with two to five antihypertensive therapies. In this new analysis, nearly half of the lorundrostat-treated participants achieved a guideline-recommended SBP below 130 mmHg”
Manish Saxena, MBBS, principal investigator; Deputy Clinical Co-Director, William Harvey Heart Centre, Queen Mary University of London; Hypertension Specialist, Barts Health NHS Trust
“In addition, 70% of lorundrostat-treated participants achieved an SBP reduction of 10 mmHg or more, a level that, if sustained in the long term, is associated with a 20% reduction in the risk of a cardiovascular event. The results of the analysis reinforce the potential of lorundrostat to deliver clinically meaningful reductions in blood pressure in patients with difficult-to-treat hypertension.”
Terry Ferguson, MD, Chief Medical Officer of Mineralys Therapeutics
“The observed reductions in morning blood pressure in Explore-OSA were consistent with the reductions in our other pivotal trials of lorundrostat in participants with uncontrolled or treatment-resistant hypertension”
Terry Ferguson, MD, Chief Medical Officer of Mineralys Therapeutics
“Results across lorundrostat trials to date demonstrate a compelling potential for lorundrostat to help a significant proportion of patients with uncontrolled or treatment-resistant hypertension, including those who also have CKD or OSA, reduce their systolic blood pressure to a level that may also reduce their risk of cardiovascular events.”
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of <130 mmHg at 12 weeks, with more than two-thirds achieving ≥10 mmHg systolic blood pressure reduction -
- In the Explore-OSA trial in participants with obstructive sleep apnea, lorundrostat 50 mg taken once daily in the evening achieved clinically meaningful reductions in morning systolic blood pressure with no measurable change in apnea-hypopnea indices -
Get started
Create a free account to read the full story.